The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.
To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.
For additional information please review our Privacy Policy.
Annual Meeting Personalized Cancer Medicine Press Conference - May 31, 2009
Orlando, Fla. — New research examining personalized approaches to cancer treatment were released today at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
“The field of personalized medicine is rapidly expanding. The more we learn about the genetic mechanics of cancer growth, the more we can harness that knowledge to personalize therapies to each patient’s disease. This will improve outcomes, help patients avoid unnecessary side effects and reduce the cost of cancer care,” said Sonali Smith, MD, associate professor of medicine at the University of Chicago Medical Center, who moderated the briefing. “The studies discussed today give us some of the first positive data on the effectiveness of therapeutic cancer vaccines, demonstrate a new use for the targeted breast cancer drug trastuzumab, and offer new genetic clues about which patients with lung cancer will benefit most from chemotherapy.”
